Skip to content

Health Care Provider Partnerships & Payments

Importance of Collaboration for Patients

At Allergan, we believe scientific exchange between health care manufacturers and health care providers, including health care institutions, physicians, patient advocacy groups, is essential to the advancement of medicine and quality of patient care. As such, we believe in ongoing engagement with all groups of health care providers to provide medical expertise and insights to Allergan and in building alliances with advocacy organizations whose mission is to educate and better patients. We believe that together we can discover meaningful innovation, educate other health care providers, or address significant unmet needs affecting patients.

We also believe in the need to recognize and provide appropriate funding and sponsorship for unmet educational and patient needs. As such, we consider medical education grants of key importance in enabling scientific exchange and progressing scientific innovation and experience. And, we are equally as committed to making charitable contributions to causes in desperate need of support and recognition.

Allergan is supportive and committed to a full disclosure of its appropriate financial compensation to health care institutions and providers for all types of engagements. On our left hand menu are links to the listings of our charitable contributions and funding of medical education grants and physician payments.

Allergan's disclosure of compensation to health care institutions and providers is in advance of a federal statute that was signed into law in the United States on March 23, 2010, namely the Patient Protection and Affordable Care Act (previously known as the "Physician Disclosure Act" or the "Sunshine Act"). This law includes a number of health-related provisions that will take effect over the next four years, including a requirement that all pharmaceutical and medical device manufacturers publicly post on a website all payments or transfers of value from the manufacturer to any physician licensed in the United States and certain healthcare institutions.

In addition, as part of Allergan's Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services which was signed into effect on August 30, 2010, Allergan will publicly disclose via a web site by December 20, 2010 all charitable contributions to US healthcare institutions and medical education grants provided by Allergan. By, April 30, 2011, Allergan will also publicly disclose certain payments to US licensed physicians on this website.